1,000 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by FNY Investment Advisers LLC

FNY Investment Advisers LLC purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,000 shares of the company’s stock, valued at approximately $38,000.

A number of other institutional investors also recently modified their holdings of PTGX. GAMMA Investing LLC boosted its holdings in shares of Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after buying an additional 487 shares during the period. Exchange Traded Concepts LLC acquired a new position in Protagonist Therapeutics during the 3rd quarter worth $43,000. CWM LLC boosted its holdings in Protagonist Therapeutics by 910.3% during the third quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after acquiring an additional 1,147 shares during the period. Harvest Fund Management Co. Ltd acquired a new stake in shares of Protagonist Therapeutics in the third quarter valued at about $69,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Protagonist Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock worth $95,000 after purchasing an additional 379 shares during the period. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Trading Up 3.5 %

Shares of PTGX opened at $37.94 on Thursday. The stock has a market cap of $2.26 billion, a PE ratio of 14.26 and a beta of 2.23. Protagonist Therapeutics, Inc. has a 1 year low of $23.17 and a 1 year high of $48.89. The stock has a 50 day simple moving average of $40.96 and a 200-day simple moving average of $41.64.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. BMO Capital Markets began coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $62.00 target price for the company. TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Wedbush reaffirmed an “outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. The Goldman Sachs Group assumed coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They issued a “neutral” rating and a $47.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, December 10th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $53.78.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 26,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $44.70, for a total value of $1,162,200.00. Following the transaction, the insider now directly owns 46,444 shares in the company, valued at $2,076,046.80. The trade was a 35.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suneel Gupta sold 103,437 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the sale, the insider now directly owns 256,174 shares in the company, valued at $11,794,250.96. This represents a 28.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 209,863 shares of company stock worth $9,689,847 over the last three months. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.